Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459

Anushka V. Goonawardena, Andrea Plano, Lianne Robinson, Ruth Ross, Iain Greig, Roger G. Pertwee, Robert E. Hampson, Bettina Platt, Gernot Riedel*

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The brain endocannabinoid system is a potential target for the treatment of psychiatric and metabolic conditions. Here, a novel CB1 receptor antagonist (ABD459) was synthesized and assayed for pharmacological efficacy in vitro and for modulation of food consumption, vigilance staging and cortical electroencephalography in the mouse. ABD459 completely displaced the CB1 agonist CP99540 at a K-i of 8.6 nmol/l, and did not affect basal, but antagonized CP55940-induced GTP gamma S binding with a K-B of 7.7 nmol/l. Acute ABD459 (3-20 mg/kg) reliably inhibited food consumption in nonfasted mice, without affecting motor activity. Active food seeking was reduced for 5-6 h postdrug, with no rebound after washout. Epidural recording of electroencephalogram confirmed that ABD459 (3 mg/kg) robustly reduced rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep. Effects were strongest during 3 h postdrug, followed by a progressive washout period. The CB1 antagonist AM251 (3 mg/kg) and agonist WIN-55,212-2 (WIN-2:3 mg/kg) also reduced REM, but variously affected other vigilance stages. WIN-2 caused a global suppression of normalized spectral power. AM251 and ABD459 lowered delta power and increased power in the theta band in the hippocampus, but not the prefrontal cortex. The neutral antagonist ABD459 thus showed a specific role of endocannabinoid release in attention and arousal, possibly through modulation of cholinergic activity. Behavioural Pharmacology 26:289-303 Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.

Original languageEnglish
Pages (from-to)289-303
Number of pages15
JournalBehavioural Pharmacology
Volume26
Issue number3
DOIs
Publication statusPublished - Apr 2015

Fingerprint

Sleep
Food
Endocannabinoids
REM Sleep
Arousal
Electroencephalography
Pharmacology
Guanosine 5'-O-(3-Thiotriphosphate)
Cannabinoid Receptor CB1
Wakefulness
Eye Movements
Prefrontal Cortex
Cholinergic Agents
Psychiatry
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl) 4-methoxyphenyl methanone
Hippocampus
Motor Activity
Health
Brain
Power (Psychology)

Keywords

  • agonist WIN-2
  • antagonist AM251
  • cannabinoids
  • cannabinoid receptor 1 receptors
  • electroencephalogram
  • endocannabinoid
  • mouse
  • neutral antagonist ABD459
  • nonrapid eye movement sleep
  • rapid eye movement sleep
  • receptor inverse agonist
  • short-term-memory
  • cannabinoid receptor
  • body-weight
  • in-vivo
  • hippocampal function
  • reinforced behavior
  • brain responses
  • power spectra
  • rat-brain

Cite this

Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. / Goonawardena, Anushka V.; Plano, Andrea; Robinson, Lianne; Ross, Ruth; Greig, Iain; Pertwee, Roger G.; Hampson, Robert E.; Platt, Bettina; Riedel, Gernot.

In: Behavioural Pharmacology, Vol. 26, No. 3, 04.2015, p. 289-303.

Research output: Contribution to journalArticle

Goonawardena, Anushka V. ; Plano, Andrea ; Robinson, Lianne ; Ross, Ruth ; Greig, Iain ; Pertwee, Roger G. ; Hampson, Robert E. ; Platt, Bettina ; Riedel, Gernot. / Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. In: Behavioural Pharmacology. 2015 ; Vol. 26, No. 3. pp. 289-303.
@article{c12b0046987b4dfb92c7e6f4430cc113,
title = "Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459",
abstract = "The brain endocannabinoid system is a potential target for the treatment of psychiatric and metabolic conditions. Here, a novel CB1 receptor antagonist (ABD459) was synthesized and assayed for pharmacological efficacy in vitro and for modulation of food consumption, vigilance staging and cortical electroencephalography in the mouse. ABD459 completely displaced the CB1 agonist CP99540 at a K-i of 8.6 nmol/l, and did not affect basal, but antagonized CP55940-induced GTP gamma S binding with a K-B of 7.7 nmol/l. Acute ABD459 (3-20 mg/kg) reliably inhibited food consumption in nonfasted mice, without affecting motor activity. Active food seeking was reduced for 5-6 h postdrug, with no rebound after washout. Epidural recording of electroencephalogram confirmed that ABD459 (3 mg/kg) robustly reduced rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep. Effects were strongest during 3 h postdrug, followed by a progressive washout period. The CB1 antagonist AM251 (3 mg/kg) and agonist WIN-55,212-2 (WIN-2:3 mg/kg) also reduced REM, but variously affected other vigilance stages. WIN-2 caused a global suppression of normalized spectral power. AM251 and ABD459 lowered delta power and increased power in the theta band in the hippocampus, but not the prefrontal cortex. The neutral antagonist ABD459 thus showed a specific role of endocannabinoid release in attention and arousal, possibly through modulation of cholinergic activity. Behavioural Pharmacology 26:289-303 Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.",
keywords = "agonist WIN-2, antagonist AM251, cannabinoids, cannabinoid receptor 1 receptors, electroencephalogram, endocannabinoid, mouse, neutral antagonist ABD459, nonrapid eye movement sleep, rapid eye movement sleep, receptor inverse agonist, short-term-memory, cannabinoid receptor, body-weight, in-vivo, hippocampal function, reinforced behavior, brain responses, power spectra, rat-brain",
author = "Goonawardena, {Anushka V.} and Andrea Plano and Lianne Robinson and Ruth Ross and Iain Greig and Pertwee, {Roger G.} and Hampson, {Robert E.} and Bettina Platt and Gernot Riedel",
year = "2015",
month = "4",
doi = "10.1097/FBP.0000000000000108",
language = "English",
volume = "26",
pages = "289--303",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams & Wilkins",
number = "3",

}

TY - JOUR

T1 - Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459

AU - Goonawardena, Anushka V.

AU - Plano, Andrea

AU - Robinson, Lianne

AU - Ross, Ruth

AU - Greig, Iain

AU - Pertwee, Roger G.

AU - Hampson, Robert E.

AU - Platt, Bettina

AU - Riedel, Gernot

PY - 2015/4

Y1 - 2015/4

N2 - The brain endocannabinoid system is a potential target for the treatment of psychiatric and metabolic conditions. Here, a novel CB1 receptor antagonist (ABD459) was synthesized and assayed for pharmacological efficacy in vitro and for modulation of food consumption, vigilance staging and cortical electroencephalography in the mouse. ABD459 completely displaced the CB1 agonist CP99540 at a K-i of 8.6 nmol/l, and did not affect basal, but antagonized CP55940-induced GTP gamma S binding with a K-B of 7.7 nmol/l. Acute ABD459 (3-20 mg/kg) reliably inhibited food consumption in nonfasted mice, without affecting motor activity. Active food seeking was reduced for 5-6 h postdrug, with no rebound after washout. Epidural recording of electroencephalogram confirmed that ABD459 (3 mg/kg) robustly reduced rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep. Effects were strongest during 3 h postdrug, followed by a progressive washout period. The CB1 antagonist AM251 (3 mg/kg) and agonist WIN-55,212-2 (WIN-2:3 mg/kg) also reduced REM, but variously affected other vigilance stages. WIN-2 caused a global suppression of normalized spectral power. AM251 and ABD459 lowered delta power and increased power in the theta band in the hippocampus, but not the prefrontal cortex. The neutral antagonist ABD459 thus showed a specific role of endocannabinoid release in attention and arousal, possibly through modulation of cholinergic activity. Behavioural Pharmacology 26:289-303 Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.

AB - The brain endocannabinoid system is a potential target for the treatment of psychiatric and metabolic conditions. Here, a novel CB1 receptor antagonist (ABD459) was synthesized and assayed for pharmacological efficacy in vitro and for modulation of food consumption, vigilance staging and cortical electroencephalography in the mouse. ABD459 completely displaced the CB1 agonist CP99540 at a K-i of 8.6 nmol/l, and did not affect basal, but antagonized CP55940-induced GTP gamma S binding with a K-B of 7.7 nmol/l. Acute ABD459 (3-20 mg/kg) reliably inhibited food consumption in nonfasted mice, without affecting motor activity. Active food seeking was reduced for 5-6 h postdrug, with no rebound after washout. Epidural recording of electroencephalogram confirmed that ABD459 (3 mg/kg) robustly reduced rapid eye movement (REM) sleep, with no alterations of wakefulness or non-REM sleep. Effects were strongest during 3 h postdrug, followed by a progressive washout period. The CB1 antagonist AM251 (3 mg/kg) and agonist WIN-55,212-2 (WIN-2:3 mg/kg) also reduced REM, but variously affected other vigilance stages. WIN-2 caused a global suppression of normalized spectral power. AM251 and ABD459 lowered delta power and increased power in the theta band in the hippocampus, but not the prefrontal cortex. The neutral antagonist ABD459 thus showed a specific role of endocannabinoid release in attention and arousal, possibly through modulation of cholinergic activity. Behavioural Pharmacology 26:289-303 Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.

KW - agonist WIN-2

KW - antagonist AM251

KW - cannabinoids

KW - cannabinoid receptor 1 receptors

KW - electroencephalogram

KW - endocannabinoid

KW - mouse

KW - neutral antagonist ABD459

KW - nonrapid eye movement sleep

KW - rapid eye movement sleep

KW - receptor inverse agonist

KW - short-term-memory

KW - cannabinoid receptor

KW - body-weight

KW - in-vivo

KW - hippocampal function

KW - reinforced behavior

KW - brain responses

KW - power spectra

KW - rat-brain

U2 - 10.1097/FBP.0000000000000108

DO - 10.1097/FBP.0000000000000108

M3 - Article

VL - 26

SP - 289

EP - 303

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 3

ER -